# Altimmune (ALT) — News

ALT · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/alt/news

## Recent headlines

- [Agility Robotics and Churchill Capital Corp XI S-4 registration statement declared effective by SEC in connection with proposed business combination](https://www.ainvest.com/news/agility-robotics-churchill-capital-corp-xi-4-registration-statement-declared-effective-sec-connection-proposed-business-combination-2610) — AInvest Wire, Oct 13, 2026
  The U.S. Securities and Exchange Commission (SEC) has declared effective the registration statement on Form S-4 filed by Agility Robotics, Inc. and Churchill Capital Corp XI (NASDAQ: CCXI) in connection with their proposed business combination . This development marks a key step toward the…
- [Altimmune 2Q loss/share 12c, est. loss/share 14c](https://www.ainvest.com/news/altimmune-2q-loss-share-12c-est-loss-share-14c-2608) — AInvest Wire, Aug 12, 2026
  Altimmune, Inc. (Nasdaq: ALT) reported a net loss of $0.32 per share for the second quarter of 2023, matching the midpoint of its guidance . This represents an improvement compared to the $0.42 net loss per share in the same period in 2022. The company’s net loss for the quarter totaled $16.1…
- [Altimmune 2Q R&D expenses $18.7M, est. $18.6M](https://www.ainvest.com/news/altimmune-2q-expenses-18-7m-est-18-6m-2608) — AInvest Wire, Aug 12, 2026
  Altimmune, Inc. (Nasdaq: ALT) reported research and development (R&D) expenses of $18.7 million for the second quarter of 2026, slightly exceeding the estimated $18.6 million . The company continues to advance its lead product candidate, pemvidutide, across multiple therapeutic areas, including…
- [Altimmune - 52-week data readout from Performa Phase 3 trial anticipated in 2029](https://www.ainvest.com/news/altimmune-52-week-data-readout-performa-phase-3-trial-anticipated-2029-2608) — AInvest Wire, Aug 3, 2026
  Altimmune, Inc. (Nasdaq: ALT) has outlined plans for its PERFORMA Phase 3 trial of pemvidutide in the treatment of metabolic dysfunction-associated steatohepatitis (MASH), with a 52-week data readout anticipated in 2029. The trial is expected to begin in the second half of 2026, following the…
- [Altimmune shares up 10% as co's drug meets main goal of mid-stage study for alcohol use disorder](https://www.ainvest.com/news/altimmune-shares-10-drug-meets-main-goal-mid-stage-study-alcohol-disorder-2607) — AInvest Wire, Jul 28, 2026
  Altimmune, Inc. (Nasdaq: ALT) reported a 10% increase in its stock price following the announcement that its mid-stage clinical trial, RECLAIM, met its primary endpoint in evaluating pemvidutide for the treatment of Alcohol Use Disorder (AUD). The trial, which enrolled approximately 100 subjects…

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).